2. Signaling Pathways
  3. Neuronal Signaling
  4. Tau Protein

Tau Protein

Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4969
    Tau Peptide (379-408)
    Tau Peptide (379-408) is aTau fragment.
    Tau Peptide (379-408)
  • HY-P4822
    Acetyl-PHF5 amide
    Acetyl-PHF5 amide is an amyloidogenic protein tau peptide. Acetyl-PHF5 amide can polymerization into filamentous structures.
    Acetyl-PHF5 amide
  • HY-162020
    SB1617
    		Inhibitor
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity.
    SB1617
  • HY-116753
    (-)Clausenamide
    		Inhibitor
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).
    (-)Clausenamide
  • HY-147321
    3'-DMTr-dG(iBu)
    3'-DMTr-dG(iBu) is a nucleoside for the synthesis of nucleic acid, such as antiviral agents used in the research of viral infection (HBV, HDV), and oligonucleotides against Alzheimer’s disease and other tauopathies.
    3'-DMTr-dG(iBu)
  • HY-161448
    Tau-aggregation-IN-3
    		Inhibitor
    Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC50=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research.
    Tau-aggregation-IN-3
  • HY-149233
    hAChE-IN-1
    		Inhibitor
    hAChE-IN-1 (Compound 24) is a potent hAChE inhibitor with an IC50 of 1.09 μM. hAChE-IN-1 inhibits tau-oligomerization with an EC50 of 2.71 μM in cellular tau FRET assay.
    hAChE-IN-1
  • HY-13486
    TAU-IN-1
    		Inhibitor
    TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases.
    TAU-IN-1
  • HY-153427
    Tau protein aggregation-IN-1
    		Inhibitor
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies.
    Tau protein aggregation-IN-1
  • HY-P4923
    Tau Peptide (1-16) (human)
    Tau Peptide (1-16) (human) is aTau fragment.
    Tau Peptide (1-16) (human)
  • HY-160481
    MG-1102
    		Inhibitor
    MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC50s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a Kd of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD).
    MG-1102
  • HY-P9995
    Posdinemab
    		Inhibitor
    Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT).
    Posdinemab
  • HY-157839
    PROTAC α-synuclein degrader 6
    		Degrader
    PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with EC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research.
    PROTAC α-synuclein degrader 6
  • HY-149273
    hBChE-IN-1
    		Inhibitor
    hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC50=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research.
    hBChE-IN-1
  • HY-P4977
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is aTau fragment.
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)
  • HY-149054
    GSK-3β inhibitor 13
    		Inhibitor
    GSK-3β inhibitor 13 (compound 47) is an orally active and potent GSK-3β inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits GSK-3β and GSK-3α with IC50s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC50=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease.
    GSK-3β inhibitor 13
  • HY-150585
    BuChE-IN-5
    		Inhibitor
    BuChE-IN-5 (compound 25b) is a potent BuChE inhibitor with an IC50 value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation Aβ and tau protein in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease.
    BuChE-IN-5
  • HY-109116A
    Hydromethylthionine dihydrobromide
    		Inhibitor
    Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide; LMTM dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders.
    Hydromethylthionine dihydrobromide
  • HY-144681A
    rel-(2R,4R)-LY3372689
    rel-(2R,4R)-LY3372689 is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease (WO2018140299A1; Compound Formula Ic).
    rel-(2R,4R)-LY3372689
Cat. No. Product Name / Synonyms Application Reactivity